Will Alkermes' Proprietary Drugs Aid Growth Amid Stiff Competition?

Alkermes plc (ALKS) has made steady progress with its portfolio of proprietary products — Vivitrol (alcohol and opioid dependence), Aristada (schizophrenia) and Lybalvi (schizophrenia and bipolar I disorder), which are witnessing a steady uptake and driving growth.Alkermes’ set of proprietary products has generated combined sales worth $1.08 billion in 2024, reflecting an increase of 18% on a year-over-year basis. The company expects to record$ 1.09-$1.15 billion in revenues from proprietary products in 202 ...